Quick facts
- Classification
- Long-acting GHRH analogue peptide
- Target / mechanism
- GHRH receptor (pituitary)
- Development status
- Early clinical study; development not completed
- Regulatory status
- Research use only
- Evidence level
- Limited (early human data)
- Therapeutic area
- Endocrine (proposed)
- Route / formulation
- Injectable preparations are marketed; none are approved
Also referred to as · Modified GRF (1-29)
What it is
CJC-1295 is a modified GHRH fragment designed for extended action. Some marketed products add a drug-affinity complex to prolong half-life further; product identity varies substantially between sellers.
How it works
It stimulates pituitary GHRH receptors, raising growth hormone and IGF-1 concentrations over a prolonged window compared with native GHRH.
What it has been studied for
- Growth hormone axis pharmacology in early-phase studies
Safety and side effects
Early studies reported injection-site reactions and flushing. Sustained elevation of growth hormone and IGF-1 has theoretical risks that have not been studied long term in healthy people.
Warnings and contraindications
Compounded / research status
Investigational uses
No completed programme supports the uses commonly promoted commercially.
Frequently asked questions
References
- Early-phase GHRH analogue pharmacology studiesPeer-reviewed clinical literature
- WADA Prohibited ListWorld Anti-Doping Agency
Reference entries are editorial placeholders describing source type and origin. Primary documents are linked as each profile is expanded.
Editorial disclaimer
This site is educational and does not provide medical advice, dosing protocols, or treatment recommendations. Regulatory status and evidence strength differ sharply between compounds. A “research use only” label does not indicate that a product is appropriate for human use. Decisions about medicines belong with a qualified clinician.